Taken together, our data showed impaired ADAM12 upregulation and miR-29a downregulation in ischemic GA muscle of mice with type 2 DM contributes to poorer experimental PAD outcomes in type 2 DM and this can be improved through gene therapy with overexpression of ADAM12 and inhibition of miR-29a. The gene discussed is ADAM12; the disease is peripheral arterial disease.